SOURCE: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

December 19, 2013 08:30 ET

Sarepta Therapeutics to Present Company Overview at the 2014 32nd Annual J.P. Morgan Healthcare Conference

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, MA--(Marketwired - Dec 19, 2013) -  Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2014 at 4:30 p.m. Pacific Time. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.

The presentations will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

Contact Information